Henry F. Blissenbach

Plus aucun poste en cours

Profil

Henry F.
Blissenbach, serves as a Director, President and Chief Executive Officer for BioScrip Inc. Dr. Blissenbach was named to this position upon the consummation of the merger between MIM Corporation and Chronimed, Inc. effective March 2005.
Dr. Blissenbach previously served as Chairman and Chief Executive Officer of Chronimed, Inc. He was appointed Chairman of the Board of Directors and Chief Executive Officer of Chronimed on July 1, 2000.
Dr. Blissenbach was named President and Chief Operating Officer of Chronimed in May 1997.
He became a director of Chronimed in September 1995.
From 1992 to 1997, he served as President of Diversified Pharmaceutical Services, Inc., a UnitedHealthcare subsidiary until 1994 and afterwards a subsidiary of SmithKline Beecham Corp.
Diversified Pharmaceutical Services, Inc. was a pharmacy benefit management firm.
Dr. Blissenbach also serves as a director of Ligand Pharmaceuticals Inc., a publicly held biopharmaceutical development company, and Opportunity Partners, Inc., a nonprofit company.

Anciens postes connus de Henry F. Blissenbach

Sociétés	Poste	Fin
Chronimed, Inc.	Président	09/08/2004
BioScrip, Inc.	President	-
LIGAND PHARMACEUTICALS INCORPORATED	Directeur/Membre du Conseil	-